ENDO 2026 research published June 2026 via ScienceDaily found most GLP-1 users with type 2 diabetes who stop treatment eventually restart, driven by weight regain.
ENDO 2026 Study Finds Most People Who Stop Ozempic or Tirzepatide for Type 2 Diabetes Eventually Restart Treatment
by | Jun 23, 2026 | Uncategorized | 0 comments
Recent Comments